V. Blatt

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

A. Brandes, M. Leonardi, M. Ermani, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glioblastoma in the elderly: current and future trends.

A. Brandes, A. Tosoni, V. Blatt, 2006, Critical reviews in oncology/hematology.

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

R. Labianca, A. Brandes, M. Reni, 2009, Cancer Chemotherapy and Pharmacology.

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

A. Brandes, L. Crinò, M. Ermani, 2006, British Journal of Cancer.

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

A. Brandes, L. Crinò, A. Pession, 2007, British Journal of Cancer.

Long‐term results of a prospective study on the treatment of medulloblastoma in adults

A. Brandes, M. Ermani, E. Franceschi, 2007, Cancer.

Is protracted low-dose temozolomide feasible in glioma patients?

A. Brandes, E. Franceschi, A. Tosoni, 2006, Neurology.

Prognostic factors for anaplastic astrocytomas

A. Brandes, E. Franceschi, A. Tosoni, 2007, Journal of Neuro-Oncology.

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

A. Brandes, M. Ermani, R. Bertorelle, 2008, Journal of Neuro-Oncology.

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

A. Brandes, M. Reni, M. Ermani, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m2 a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study

L. Crinò, M. Ermani, E. Franceschi, 2005 .